Telehealth Ketamine for OCD

Obsessive-compulsive disorder is one of the most debilitating anxiety-related conditions, and it is notably resistant to standard treatments in a significant portion of patients. Ketamine has been studied for OCD, but the evidence base is more limited and the results more variable than for depression. This guide covers what is known, what is not, and who might benefit.

The Challenge of Treating OCD

OCD is characterized by intrusive, unwanted thoughts (obsessions) and repetitive behaviors or mental acts performed to reduce distress (compulsions). First-line treatments include:

• Exposure and Response Prevention (ERP) therapy—the gold standard
• SSRIs at typically higher doses than used for depression
• For treatment-resistant cases: augmentation with antipsychotics, deep brain stimulation, or transcranial magnetic stimulation (TMS)

A significant minority of OCD patients do not achieve adequate relief even with aggressive combination treatment. This population represents the potential target for ketamine. For a broader overview of how ketamine addresses difficult-to-treat conditions, see our article on treatment-resistant conditions.

The Evidence for Ketamine in OCD

What Research Shows

The evidence for ketamine in OCD is preliminary but intriguing:

• A 2013 randomized crossover trial by Rodriguez et al. at Columbia University was the first rigorous study of ketamine for OCD. It found that IV ketamine produced rapid and significant OCD symptom reduction in patients with primarily obsessional OCD (without overt compulsions)
• Subsequent case reports and small series have shown variable results—some patients with OCD respond dramatically, others show minimal benefit
• A notable finding: the patients who responded best in the Rodriguez trial had predominantly pure obsessional OCD, while those with prominent compulsions showed less benefit

Why OCD May Respond Differently

OCD has distinct neurobiological features from depression and anxiety. The cortico-striato-thalamo-cortical (CSTC) circuit dysfunction central to OCD's pathophysiology involves loops between prefrontal cortex, striatum, and thalamus. Ketamine's effects on glutamatergic transmission in these circuits may disrupt the hyperactive loop dynamics underlying OCD, but the disruption is less complete or consistent than for depressive pathology.

Additionally, the behavioral component of OCD (compulsions) represents learned behavior patterns that may require ERP therapy to extinguish even if the obsessional drive is reduced by ketamine.

The Integration Challenge for OCD

OCD's behavioral learning component means that ketamine alone is unlikely to produce sustained benefit without concurrent ERP therapy. The neuroplastic window that ketamine opens may be an opportunity to engage more effectively with ERP—to approach feared stimuli with reduced compulsive drive—but this requires active therapeutic engagement, not just passive exposure.

Patients seeking ketamine for OCD should have an OCD-specialist therapist trained in ERP to work with during the treatment course. For more on why therapy alongside ketamine matters, see our integration support guide.

Who Might Be Appropriate for Telehealth Ketamine for OCD

Potentially Appropriate Candidates

• Treatment-resistant OCD with documented failure of multiple SSRIs and adequate ERP trials
• OCD with predominantly obsessional presentation (pure obsessional, limited overt compulsions)
• OCD with significant comorbid depression (where ketamine's antidepressant effects may provide secondary benefit to the OCD)
• Stable patients with a committed OCD specialist therapist willing to coordinate care

Less Appropriate Candidates

• OCD with prominent compulsions that require behavioral intervention as the primary treatment approach
• Patients who have not completed an adequate ERP trial (ketamine should not substitute for ERP in patients who have not been through it)
• Patients with OCD involving intrusive thoughts with violent or sexual content who may be distressed by the altered state amplifying intrusive material

What to Expect

OCD patients considering ketamine should have explicit conversations with their provider about:

• What the evidence does and does not show for their specific OCD presentation
• How the ketamine sessions will be structured given OCD symptomatology
• How OCD-specific material might emerge during sessions and how it will be handled
• What the integration plan is, including coordination with an OCD therapist

Not all telehealth ketamine platforms have clinicians with significant OCD experience. For this indication specifically, asking about the clinical team's OCD expertise is worthwhile.

Platforms and OCD

OCD is a less commonly listed indication on telehealth platforms than depression or anxiety. Some platforms will evaluate OCD patients on a case-by-case basis. For OCD specifically, platforms with stronger clinical oversight and integration support—particularly those with access to licensed therapists—are preferable to self-service models.

Given the preliminary evidence base and the complexity of OCD, patients seeking ketamine for OCD specifically should be working with an OCD specialist and should approach ketamine as an adjunct to ERP rather than a replacement for it.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches